When a medical device manufacturer throws nine figures at AI startups, it’s rarely about technology. It’s about liquidity seeking a narrative. Jiuan Medical—a company whose pandemic-era windfall turned it into a cash hoarder—recently deployed ~9 billion yuan across three of China’s most hyped large-language-model (LLM) ventures: DeepSeek, Kimi (Moonshot AI), and LeapStar (Baichuan Intelligent). The market cheered with a five-day gain before volatility crept in. But step back and what you see is not a strategic pivot. It’s a textbook case of narrative liquidity converging with late-cycle capital allocation.
Context: From antigen tests to AI lotteries Jiuan Medical rode the COVID wave to massive profits selling antigen test kits. By 2023, those revenues normalized, leaving the company sitting on a pile of cash with no clear growth path. Enter the AI narrative. The company announced indirect minority stakes—7.5 billion yuan for 0.21% of DeepSeek, $30 million across two rounds for Kimi, and 1 billion yuan for LeapStar. Critical detail: Jiuan explicitly stated it would not participate in operations. This is the hallmark of a pure financial punt, not a business transformation.
To understand the mechanics, we must map the macro liquidity landscape. Global cash reserves held by non-financial corporates hit an all-time high after 2020-2021. With real yields still negative in many economies and crypto markets in a grinding bear, the hunt for yield and narrative has pushed capital into the last high-growth story standing: artificial intelligence. But unlike venture capital firms that build sector expertise, corporate treasuries often lack the frameworks to evaluate technology risk. They rely on signaling and FOMO. Based on my experience auditing DeFi liquidity pools during the 2020 summer frenzy, I saw the same pattern: capital flowing into projects not because of fundamentals but because of the narrative premium attached to a hot sector. Liquidity is the only truth in a world of noise—and here the noise says AI is the only game in town.
Core: The investment as a financial derivative Let’s break down the real nature of these deals. The 7.5 billion yuan for 0.21% of DeepSeek implies a valuation of ~357 billion yuan ($50 billion). That’s more than the market cap of many publicly traded enterprise software companies with proven revenue. For context, DeepSeek’s primary revenue streams remain minuscule—mostly developer API usage and cloud credits. This valuation is not a reflection of current cash flows but a bet on future monopoly rents in a winner-take-most scenario. The payout structure resembles a long-dated out-of-the-money call option: small upfront premium (0.21% of a private company) with enormous upside if DeepSeek becomes the foundational LLM of China, but near-total loss if it doesn’t. The same logic applies to Kimi and LeapStar, though their valuations are slightly less extreme.
Chaos is just liquidity waiting for a narrative—and Jiuan is supplying the liquidity while the narrative is already peaking. Historically, when non-tech conglomerates start buying into a sector through tiny passive stakes, it often marks the top of the hype cycle. During the crypto bull run of 2021, we saw companies like MicroStrategy and Tesla buy Bitcoin directly. But the real signal of froth was when firms like Meitu (a beauty app) and Square (payments) allocated spare cash to Bitcoin. Those allocations coincided with local tops. Similarly, when a medical device company allocates a fraction of its cash to AI startups, it suggests the easy money has already been made by earlier-stage VCs. The latecomers are buying narrative exposure at inflated prices.
Moreover, the lack of operational involvement means Jiuan has zero influence over technical direction or corporate governance. They cannot mitigate dilution risk in subsequent funding rounds. If DeepSeek or Kimi raise more capital at a lower valuation—a real possibility given the fierce competition from Alibaba, Baidu, and ByteDance—Jiuan’s stake could be significantly diluted. This is not a hedge. It is a speculative bet with no control over the underlying asset.
Contrarian angle: The decoupling that never happens The market narrative portrays this investment as ‘catching the AI wave.’ But the contrarion view is that Jiuan Medical’s move is a late-cycle indicator of narrative exhaustion. Consider the following: In crypto, we often talk about decoupling—the idea that Bitcoin or Ethereum will rise independently of traditional markets. It rarely happens in practice. Similarly, the AI narrative is not decoupled from the broader liquidity cycle. As central banks globally pivot to tighter monetary conditions (the Bank of Japan slowly raising rates, the Fed maintaining higher-for-longer), the liquidity that inflated AI valuations will contract. When it does, companies that bought in at the peak will face impairment charges.
Value is the illusion we agree to sustain—and the illusion here is that these AI startups will achieve the scale of Big Tech within a few years. History is littered with examples of corporate venture arms making splashy investments at the top of cycles. In 2021, many traditional firms poured money into NFT and metaverse startups. Today, those investments are largely written off. The same fate awaits overpriced LLM stakes unless a true step-change in revenue materializes. My experience analyzing the DeFi liquidity paradox taught me that user retention after incentive cessation is the ultimate test. For AI companies, the analogous test is whether they can convert hype-driven API usage into sticky enterprise contracts. So far, the conversion rates are low across the industry.
Takeaway: Positioning for the next turn For the informed investor, Jiuan Medical’s AI bet is a signal to rotate out of narrative-driven tech exposure and into assets with intrinsic value—whether that’s Bitcoin as a non-sovereign store of value or real-world assets tokenized on-chain. The liquidity that chased AI will eventually flow back to safer harbors when the narrative fades. Smart money is already positioning for that rotation. When the narrative liquidity dries up, what will be left? A pile of paper with no revenue and a shrinking pool of believers. Follow the liquidity, not the story.